about
Streptococcal pharyngitis in schoolchildren in Bamako, Mali.Vaccination against the M protein of Streptococcus pyogenes prevents death after influenza virus: S. pyogenes super-infection.Relationship between expression of the family of M proteins and lipoteichoic acid to hydrophobicity and biofilm formation in Streptococcus pyogenesInactivation of DltA modulates virulence factor expression in Streptococcus pyogenesStreptococcal protective antigens (Spa): a new family of type-specific proteins of group A streptococci.The NH(2)-terminal region of Streptococcus pyogenes M5 protein confers protection against degradation by proteases and enhances mucosal colonization of mice.Multivalent group A streptococcal vaccine elicits bactericidal antibodies against variant M subtypesPrevalence of rheumatic heart disease in children and young adults in NicaraguaIdentification of a gene within a pathogenicity island of enterotoxigenic Escherichia coli H10407 required for maximal secretion of the heat-labile enterotoxin.Protective efficacy of group A streptococcal vaccines containing type-specific and conserved M protein epitopes.Progress in the development of effective vaccines to prevent selected gram-positive bacterial infections.Immunogenicity of a 26-valent group A streptococcal vaccine.A novel live vector group A streptococcal emm type 9 vaccine delivered intranasally protects mice against challenge infection with emm type 9 group A streptococci.Group A streptococcus expresses a trio of surface proteins containing protective epitopes.Protective immunogenicity of group A streptococcal M-related proteins.Comparison of the leader sequences of four group A streptococcal M protein genes.Prospects for a group A streptococcal vaccine: rationale, feasibility, and obstacles--report of a National Institute of Allergy and Infectious Diseases workshop.Protective immunogenicity and T lymphocyte specificity of a trivalent hybrid peptide containing NH2-terminal sequences of types 5, 6, and 24 M proteins synthesized in tandemRationale and design of the African group A streptococcal infection registry: the AFROStrep studyCurrent status of group A streptococcal vaccine development.The importance of the group a streptococcus capsule in the pathogenesis of human infections: a historical perspective.Intranasal immunization with multivalent group A streptococcal vaccines protects mice against intranasal challenge infections.Group A streptococcal emm type prevalence among symptomatic children in Cape Town and potential vaccine coverageGroup A streptococcal vaccines: paving a path for accelerated development.Trivalent M-related protein as a component of next generation group A streptococcal vaccines.Status of research and development of vaccines for Streptococcus pyogenes.A systematic and functional classification of Streptococcus pyogenes that serves as a new tool for molecular typing and vaccine development.Serum opacity factor (SOF) of Streptococcus pyogenes evokes antibodies that opsonize homologous and heterologous SOF-positive serotypes of group A streptococci.Prospective Longitudinal Analysis of Immune Responses in Pediatric Subjects After Pharyngeal Acquisition of Group A Streptococci.The Cape Town Clinical Decision Rule for Streptococcal Pharyngitis in Children.Safety and immunogenicity of 26-valent group a streptococcus vaccine in healthy adult volunteers.One More Disguise in the Stealth Behavior of Streptococcus pyogenes.The reemergence of serious group A streptococcal infections and acute rheumatic fever.Type-specific immunogenicity of a chemically synthesized peptide fragment of type 5 streptococcal M protein.Added value of the emm-cluster typing system to analyze group A Streptococcus epidemiology in high-income settings.Age-associated differences in prevalence of group A streptococcal type-specific M antibodies in children.Progress toward a global group a streptococcal vaccine.Structure-based design of broadly protective group a streptococcal M protein-based vaccines.Immune Cross-Opsonization Within emm Clusters Following Group A Streptococcus Skin Infection: Broadening the Scope of Type-Specific Immunity.Seven-year surveillance of north american pediatric group a streptococcal pharyngitis isolates.
P50
Q30301331-C1AD86CF-2DDC-477B-8617-80A70D80867EQ30586381-AF64A28C-CB5F-4FCD-A8C0-D046BD9C6195Q33398535-EDCDDDC4-A076-4ACE-BE4C-4FC96D7BE5C0Q33436236-52403596-144B-44D5-B8FD-520A9D2DEE6EQ33513502-82AAA104-2426-4353-81D6-B24B990D462FQ33804050-BE0A04C3-4D57-46B7-9CB3-49A9E3D161FEQ33910815-2BBEC9EE-D854-44D7-8066-FC5810E22E7AQ33956977-49593409-61BC-42BD-8CF9-C51901796F12Q34004347-F06BABF5-D078-416E-8C8B-74238062A81CQ34005434-FE557381-1DA3-4139-8092-5962626E31B7Q34112608-642A0CAB-14EF-484C-AB1E-30DBDFC838C7Q34121015-9B7EE345-4543-4966-B98E-30882C324F55Q34260712-AB729A24-5E22-447F-889A-25E97CEAF4E6Q34701389-002CA274-BBAA-4BF4-9560-F665B4F19216Q35122760-615FD2D4-6D35-4863-8C5D-587CA7F758EBQ36005988-50B8C773-B6CA-4158-B856-1FD24A30B893Q36257688-E7A78DAC-872D-4D11-9426-947B2821DD17Q36353910-56A1F86D-8D48-4252-9FDB-FE1E6B33D97BQ36625203-A60187D4-5A2A-4E08-8BD9-296676A64AA2Q37056482-56820FC6-9585-4575-9BA7-29818CCCC7ACQ37150291-5C6EEE2A-2CB4-44A0-88D2-F8E032DF39AAQ37427385-2736FA52-E2F6-4289-BDEF-18FB02953BBFQ37625963-BB3FD904-835C-4129-A8C7-6DB6CC546FC9Q38100042-8249B461-E412-404C-87D4-21BD926CA20BQ38760588-1BD186DE-E284-4031-9DC6-044564397AD2Q38887703-1C1DA821-EBC0-4B88-BF17-4AA1901A5528Q39197885-D377E6FB-FA95-4E8D-ACB3-A1817DC45AD6Q39863755-E1BDAFF6-2977-4B44-8E8B-611CFF4E2185Q40068749-93E481E2-8966-4BE1-AF57-54E7CFAEC5ECQ40442294-6A6A7E70-8DFB-4986-9C4D-09C427150B23Q40498619-F270FA35-F44A-4A30-BAC7-BD9C6B60E09DQ40670494-4AD60F53-6EA3-4039-93B7-0DE7FB8697E8Q40676135-FBDF0716-30D9-4E08-9AAE-C37BB9401D9BQ42936646-7F95A6A4-23AD-47AF-AAEE-38EEFB886A1FQ42998510-FD9B4CB2-AFFB-4393-A31E-784751A9D813Q45715808-03012E0F-026E-407A-BFCD-26D5D3436AA3Q46707430-D86819CA-99BD-4556-9651-622737A12D48Q47100337-F5F57971-A802-4405-B6F0-A51F11C56DBCQ47666939-CEE4C9A5-F42B-40EC-9283-D1CE15E72DDCQ47695279-4458F7D6-0C1B-4BC9-8369-EF476B372547
P50
description
onderzoeker
@nl
researcher
@en
հետազոտող
@hy
name
James B Dale
@ast
James B Dale
@en
James B Dale
@es
James B Dale
@nl
type
label
James B Dale
@ast
James B Dale
@en
James B Dale
@es
James B Dale
@nl
prefLabel
James B Dale
@ast
James B Dale
@en
James B Dale
@es
James B Dale
@nl
P106
P1153
26637682000
P21
P31
P496
0000-0001-9860-9233